Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer
- 31 December 1994
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (9) , 1285-1288
- https://doi.org/10.1016/0959-8049(94)90174-0
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1992
- A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.Journal of Clinical Oncology, 1991
- Activity of high-dose epirubicin in advanced non-small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- High-Dose Epirubicin as a Single Agent in the Treatment of Patients with Advanced Breast CancerTumori Journal, 1991
- A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladderAnnals of Oncology, 1991
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.Journal of Clinical Oncology, 1988
- A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinomaBritish Journal of Cancer, 1987
- Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.Journal of Clinical Oncology, 1987
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977